Back to Directory

Sarah Bradford

Email

sbradford@fhi360.org

Phone

919-321-3673

Institution

FHI 360

Title

Senior Clinical Research Manager

Address

FHI360
359 Blackwell St
Ste 200
Durham, NC 27701
United States of America

Request an Update

Affiliated Studies

IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV

DAIDS Number

38747

Research Area

Tuberculosis

Study Status

In Development

P1092: Phase IV Evaluation of the Steady State Pharmacokinetics of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in Severely Malnourished HIV-1 Infected Children

DAIDS Number

11689

Research Area

Therapeutics

Study Status

Concluded

IMPAACT 2001: A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection

DAIDS Number

12026

Research Area

Tuberculosis

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2007: Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection

DAIDS Number

20734

Research Area

Treatment

Study Status

Concluded

P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) Given in Combination with an Individualized Rifampin-Resistant Tuberculosis (RR-TB) Therapy in Infants, Children and Adolescents with RR-TB Disease, Living with or without HIV

DAIDS Number

11884

Research Area

Tuberculosis

Study Status

Closed to Accrual

Show All